About: Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon?
Creator	Nabavi, Seyed Banach, Maciej Habtemariam, Solomon Sahebnasagh, Adeleh Berindan-Neagoe, Ioana Cismaru, Andrei Dowran, Razieh Fazel Nabavi, Seyed Shahmohamadnejad, Shiva
source	Elsevier; Medline; PMC
abstract	Abstract Various interferon (IFN)-inducible transmembrane (IFITM) proteins are known to be expressed in human tissues though only IFITM 1–3 are inducible by IFN. Numerous studies have shown that activation of IFITM3 could suppress infection by influenza and coronaviruses such as the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). In view of the potential application of IFITM proteins’ induction to target SARS-CoV-2 infection that causes COVID-19, this article layout insights into the known antiviral mechanisms and therapeutic agents related to IFITM. Blocking viral entry through various mechanisms and the potential application of the FDA approved immunosuppressant agent, mycophenolic acid, as inducer of IFITM3 are among those discussed.
has issue date	2020-08-14(xsd:dateTime)
bibo:doi	10.1016/j.biochi.2020.08.006
bibo:pmid	32805303
has license	els-covid
sha1sum (hex)	f8b22000f909f19aff2b83bedb57867dc41990d6
schema:url	https://doi.org/10.1016/j.biochi.2020.08.006
resource representing a document's title	Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon?
has PubMed Central identifier	PMC7426705
has PubMed identifier	32805303
schema:publication	Biochimie
resource representing a document's body	covid:f8b22000f909f19aff2b83bedb57867dc41990d6#body_text
is schema:about of	named entity 'target' named entity 'influenza' named entity 'application' named entity 'immunosuppressant' named entity 'Various' named entity 'inducible' named entity 'INTERFERON ' named entity 'MYCOPHENOLIC ACID' named entity 'proteins' named entity 'induction' named entity 'antiviral' named entity 'FDA' named entity 'Journal' named entity 'IFN' named entity 'IFN' named entity 'therapeutic agents' named entity 'MERS-CoV' named entity 'transmembrane' named entity 'IFITM3' named entity 'immunosuppressant' named entity 'human tissues' named entity 'infection' named entity 'viral entry' named entity 'mutation' named entity 'interferon' named entity 'enzyme' named entity 'organ' named entity 'viral entry' named entity 'organ rejection' named entity 'cell line' named entity 'MERS-CoV' named entity '293T cells' named entity 'exogenous' named entity 'ACE2' named entity 'IFITM3' named entity 'HCoV-OC43' named entity 'proteolytic cleavage' named entity 'Mycophenolic acid' named entity 'IFITM1' named entity 'vertebrates' named entity 'MERS-CoV' named entity 'MHV' named entity 'plasma membrane' named entity 'Middle East Respiratory Syndrome Coronavirus' named entity 'antiviral' named entity 'hemostasis' named entity 'COVID' named entity 'highly conserved' named entity 'SARS-CoV-2' named entity 'coronavirus' named entity 'IFN' named entity 'fusion pore' named entity 'host cells' named entity 'prophylaxis' named entity 'IFITM3' named entity 'immunosuppressant' named entity 'ester' named entity 'IFITM3' named entity 'FDA' named entity 'cholesterol synthesis' named entity 'receptor expression' named entity 'lysosomes' named entity 'IFITM5' named entity 'cell entry' named entity 'IFITM3' named entity 'innate immunity' named entity 'IFITM3' named entity 'infection' named entity 'Coronaviridae' named entity 'SARS-CoV-2' named entity 'lymphocytes' named entity 'viruses' named entity 'upregulation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software